BioXcel Therapeutics shares are trading higher after the company announced that the Centers for Medicare & Medicaid Services issued a permanent and product-specific J-Code for IGALMI sublingual film.
Portfolio Pulse from Benzinga Newsdesk
BioXcel Therapeutics announced that the Centers for Medicare & Medicaid Services has issued a permanent and product-specific J-Code for IGALMI sublingual film, leading to a rise in the company's shares.
October 30, 2023 | 2:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioXcel Therapeutics' shares are trading higher after the company received a permanent and product-specific J-Code for IGALMI sublingual film from the Centers for Medicare & Medicaid Services.
The issuance of a permanent and product-specific J-Code for BioXcel Therapeutics' IGALMI sublingual film by the Centers for Medicare & Medicaid Services is a positive development for the company. This could potentially increase the accessibility and usage of the product, leading to higher revenues. As a result, the company's shares are trading higher.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100